Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$29.57 USD
+2.04 (7.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $29.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Castle Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 220 | 137 | 94 | 63 | 52 |
Cost Of Goods | 45 | 32 | 16 | 10 | 7 |
Gross Profit | 175 | 105 | 78 | 53 | 45 |
Selling & Adminstrative & Depr. & Amort Expenses | 243 | 178 | 118 | 60 | 37 |
Income After Depreciation & Amortization | -68 | -73 | -40 | -7 | 7 |
Non-Operating Income | 11 | 4 | 0 | -1 | 3 |
Interest Expense | 0 | 0 | 0 | 3 | 5 |
Pretax Income | -57 | -69 | -40 | -10 | 5 |
Income Taxes | 0 | -2 | -9 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -57 | -67 | -31 | -10 | 5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -57 | -67 | -31 | -10 | 5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -61 | -64 | -37 | -5 | 10 |
Depreciation & Amortization (Cash Flow) | 7 | 9 | 3 | 1 | 2 |
Income After Depreciation & Amortization | -68 | -73 | -40 | -7 | 7 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.80 | 26.05 | 25.14 | 18.93 | 8.66 |
Diluted EPS Before Non-Recurring Items | -2.14 | -2.58 | -1.23 | -0.47 | -0.81 |
Diluted Net EPS (GAAP) | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 |
Fiscal Year end for Castle Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 87.00 | 72.97 | 66.12 | 61.49 | 50.14 |
Cost Of Goods | 14.52 | 13.89 | 12.42 | 11.32 | 11.06 |
Gross Profit | 72.48 | 59.08 | 53.70 | 50.17 | 39.08 |
SG&A, R&D, and Dept/Amort Expenses | 67.48 | 64.56 | 59.35 | 59.81 | 60.24 |
Income After SG&A, R&D, and Dept/Amort Expenses | 5.00 | -5.48 | -5.65 | -9.64 | -21.16 |
Non-Operating Income | 3.14 | 3.00 | 3.12 | 2.77 | 2.40 |
Interest Expense | 0.27 | 0.01 | 0.00 | 0.00 | 0.00 |
Pretax Income | 7.89 | -2.49 | -2.54 | -6.87 | -18.76 |
Income Taxes | -1.03 | 0.05 | 0.04 | 0.03 | 0.02 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 8.92 | -2.53 | -2.58 | -6.91 | -18.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 8.92 | -2.53 | -2.58 | -6.91 | -18.78 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 28.74 | 27.49 | 27.03 | 26.83 | 26.73 |
Diluted EPS Before Non-Recurring Items | 0.31 | -0.09 | -0.10 | -0.26 | -0.70 |
Diluted Net EPS (GAAP) | 0.31 | -0.09 | -0.08 | -0.26 | -0.70 |